Charles River Laboratories  

(Public, NYSE:CRL)   Watch this stock  
Find more results for CRL
-0.09 (-0.13%)
Real-time:   2:15PM EST
NYSE real-time data - Disclaimer
Currency in USD
Range 69.16 - 70.47
52 week 49.60 - 70.73
Open 69.59
Vol / Avg. 95,428.00/343,714.00
Mkt cap 3.29B
P/E 27.76
Div/yield     -
EPS 2.51
Shares 46.92M
Beta 1.05
Inst. own 100%
Feb 11, 2015
Q4 2014 Charles River Laboratories International Inc Earnings Call - 9:00AM EST - Add to calendar
Feb 10, 2015
Q4 2014 Charles River Laboratories International Inc Earnings Release - 4:00PM EST - Add to calendar
Jan 14, 2015
Charles River Laboratories International Inc at JPMorgan Healthcare Conference (Q&A Session)
Jan 14, 2015
Charles River Laboratories International Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 9.86% 9.04%
Operating margin 14.10% 12.99%
EBITD margin - 24.68%
Return on average assets 6.99% 6.55%
Return on average equity 19.12% 16.77%
Employees 7,700 -
CDP Score - -


United States - Map
+1-978-6586000 (Phone)
+1-978-9885665 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Charles River Laboratories International, Inc. is a global provider of solutions, which accelerate the early-stage drug discovery and development process. The focus of its business is in vivo biology; its portfolio includes research models and services required to enable in vivo drug discovery and development. The Company operates in two segments: Research Models and Services (RMS) and Preclinical Services (PCS). Through its RMS segment, the Company has been supplying research models to the drug development industry. Its PCS business segment provides services that enable its clients to outsource their critical, regulatory-required safety assessment and related drug development activities to the Company. In April 2014, Charles River Laboratories International Inc completed the acquisition of the CRO services division of Galapagos NV which includes both Argenta and BioFocus.

Officers and directors

James C. Foster Chairman of the Board, President, Chief Executive Officer
Age: 63
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Thomas F. Ackerman Chief Financial Officer, Corporate Executive Vice President
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
David P. Johst Corporate Executive Vice President, Chief Administrative Officer, General Counsel
Age: 52
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Nancy A. Gillett Ph.D. Chief Scientific Officer, Corporate Executive Vice President
Age: 58
Bio & Compensation  - Reuters
Jorg M. Geller Ph.D. Corporate Executive Vice President - Global Productivity and Efficiency
Age: 59
Bio & Compensation  - Reuters
Davide A. Molho Corporate Executive Vice President ; President, Global Research Models & Services and Preclinical Services Operations
Age: 44
Bio & Compensation  - Reuters
John Crowley CPA Corporate Senior Vice President, Chief Accounting Officer, Corporate Controller
Age: 40
Bio & Compensation  - Reuters
Colin Dunn Ph.D., Corporate Senior Vice President and General Manager, Research Models & Services, Europe and Asia
Bio & Compensation  - Reuters
Foster Jordan Corporate Senior Vice President, Endotoxin & Microbial Detection
Bio & Compensation  - Reuters
Geoff Goldsmith Corporate Executive Vice President, Global Productivity and Efficiency
Bio & Compensation  - Reuters